These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 19530982

  • 1. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
    Gold DT, Trinh H, Safi W.
    Curr Med Res Opin; 2009 Aug; 25(8):1831-9. PubMed ID: 19530982
    [Abstract] [Full Text] [Related]

  • 2. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT, Safi W, Trinh H.
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [Abstract] [Full Text] [Related]

  • 3. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S, Jeglitsch M, McCloskey E.
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [Abstract] [Full Text] [Related]

  • 4. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE, Yu J, Campbell HE, Abarca J, White TJ.
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [Abstract] [Full Text] [Related]

  • 7. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Chung YS, Lim SK, Chung HY, Lee IK, Park IH, Kim GS, Min YK, Kang MI, Chung DJ, Kim YK, Choi WH, Shong MH, Park JH, Byun DW, Yoon HK, Shin CS, Lee YS, Kwon NH.
    Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
    [Abstract] [Full Text] [Related]

  • 8. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
    Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachmann GA.
    South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
    [Abstract] [Full Text] [Related]

  • 9. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills.
    Weiss TW, Henderson SC, McHorney CA, Cramer JA.
    Curr Med Res Opin; 2007 Sep; 23(9):2193-203. PubMed ID: 17686228
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS.
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [Abstract] [Full Text] [Related]

  • 12. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.
    Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W.
    Clin Ther; 2006 Oct; 28(10):1686-94. PubMed ID: 17157124
    [Abstract] [Full Text] [Related]

  • 13. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY.
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S, Olson M, van Staa TP.
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [Abstract] [Full Text] [Related]

  • 16. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM.
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
    Park JH, Park EK, Koo DW, Lee S, Lee SH, Kim GT, Lee SG.
    BMC Musculoskelet Disord; 2017 Apr 11; 18(1):152. PubMed ID: 28399834
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.